In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improved clinical scores at three months, but the difference did not last and immunological measures did not change.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Thymostimulin (TP-1)' with aliases TP-1, thymostimulin, calf thymus extract TP-1 · 2026-09-27 12:04 · somebody
kind set kind set to other: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added classification: Thymostimulin (TP-1) is a polypeptide extract of thymus. · 2026-09-27 12:04 · somebody
fact added summary: In a double-blind, placebo-controlled trial in 29 patients with severe atopic eczema, ten weeks of thymostimulin improve · 2026-09-27 12:04 · somebody
fact added mechanism: In mice with Lewis lung carcinoma, thymostimulin delayed the primary tumour and, after the tumour was removed or togethe · 2026-09-27 12:04 · somebody
citation added pmid 1835403 cited as emerging: Thymostimulin in severe atopic eczema: transient benefit (RCT, n=29) · 2026-09-27 12:04 · somebody
citation added pmid 7248976 cited as preclinical: Thymostimulin increased survival of tumour-bearing mice · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.